hotspot -WSS

hotspot

author：comprehensive 2025-08-12 06:34:34 - browse：9

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Indian pharmaceutical industry in denial over drug

hotspot

WSS

With psoriasis trial ahead, Alumis raises $259 million

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

The drug industry has found itself all alone in Washington

Sen. Paul opposes bill to ban Chinese biotechs

Judge rejects Trump's request to move Stormy Daniels hush

UnitedHealth quietly bought dozens of outpatient centers

entertainment

hotspot

focus

Novavax promises a turnaround & Lilly roils the obesity market

Winning ticket for $1 billion Powerball jackpot sold in California

Guidelines to prevent youth baseball injuries need more muscle

IVF, abortion rights issues kick off Biden’s State of the Union

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why Congress must ban federal programs from using QALYs

Wildfire smoke exposes gaps in outdoor worker protections

How to bring more disabled researchers into academia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Vir antibody drug aimed at influenza A fails in clinical trial

explore

UnitedHealth quietly bought dozens of outpatient centers

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Amylyx ALS drug failure raises questions and concerns

Indian pharmaceutical industry in denial over drug

Precocious puberty in girls comes with mental health risks

Judge rejects Trump's request to move Stormy Daniels hush

focus

hotspot

focus

leisure time